CMS coverage policies restrict patient access to important treatment options for Alzheimer ’s disease

There ’s been a lot of discussion this year about the Centers for Medicare& Medicaid Services (CMS)national coverage determination (NCD) for new Alzheimer ’s treatments finalized earlier this year in April. Their policy, finalized this past April, puts in place barriers between Alzheimer ’s patients in Medicare and potentially life-changing treatment. But, unfortunately, this new NCD isn’t the only coverage barrier these patients face.
Source: The Catalyst - Category: Pharmaceuticals Authors: Tags: Alzheimer's Medicare Source Type: news